Authors
Loading...
Observational analysis detected FLT3-ITD clones in 27.2% of patients at day +30, indicating that personalized maintenance therapy may improve outcomes in AML.
Pang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: